CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 78 enrolled
Drug / intervention
pembrolizumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02454179
NCT02454179Phase 2Completed
CompareCT.gov

A Phase 2 Proof-of-Concept Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Advanced Head and Neck Squamous Cell Carcinoma

Acerta Pharma BV·interventional·Posted May 27, 2015·Updated Sep 12, 2019

In Brief

A Phase 2 clinical trial evaluating pembrolizumab and Acalabrutinib for Squamous Cell Carcinoma of the Head and Neck. Completed, enrolled 78 participants across 1 site.

Detailed Summary

Study of the combination of acalabrutinib (ACP-196) and pembrolizumab in subjects with advanced head and neck squamous cell carcinoma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSquamous Cell Carcinoma of the Head and Neck
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedMay 27, 2015
Enrollment StartMay 1, 2015
Primary CompletionMay 1, 2018
Study CompletionJul 1, 2018
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 11.1 years ago

Interventions

pembrolizumabdrug

Acalabrutinibdrug